Biosimilars Poll: What is Your Opinion on Clinical Efficacy Trials?

Article

There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.

Take the Biosimilars Poll!

Person voting with a ballot box

There are diverging opinions on whether comparative efficacy trials add much of value to the evidence for biosimilar approval in the United States.

Which of the following best describes your opinion?

The requirements for FDA approval of biosimilars are appropriate.
There is no longer any need for comparative clinical efficacy trials.
The requirements for demonstration of biosimilarity need to be increased.

Check out the results from our last poll:

Infographic with a pie chart of the responses from our last poll

Click to enlarge

Related Content
In Canada, the Northwest Territories Switch to Biosimilars

In Canada, More Mandatory Switching

December 23rd 2021
Article

In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.

Alvotech Gains EC Approval for Adalimumab Biosimilar

Alvotech Gains EC Approval for Adalimumab Biosimilar

December 16th 2021
Article

Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

June 23rd 2021
Article

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Poll: Identify the Main Cause for Reverse Switching

Poll: Identify the Main Cause for Reverse Switching

June 8th 2021
Article

Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.

Poll: Where Do You Stand on Product Exclusivity Protections?

Poll: Where Do You Stand on Product Exclusivity Protections?

May 12th 2021
Article

When it comes to biologics, there is a constant push and pull over patent rights. Some believe this is part of a healthy market-driven economy. Others are skeptical.

Poll: How Much Progress With Biosimilars Has the United States Made?

Poll: How Much Progress With Biosimilars Has the United States Made?

April 28th 2021
Article

With 20 biosimilar launches in the United States since 2015, opinions vary as to the strength of utilization.

© 2023 MJH Life Sciences

All rights reserved.